These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 33971218)

  • 1. The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Liu Z; Yan A; Zhao J; Yang S; Song L; Liu Z
    Exp Neurol; 2021 Aug; 342():113740. PubMed ID: 33971218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
    J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
    Tronci E; Napolitano F; Muñoz A; Fidalgo C; Rossi F; Björklund A; Usiello A; Carta M
    Exp Neurol; 2017 Nov; 297():73-81. PubMed ID: 28757258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
    Ye T; Bartlett MJ; Sherman SJ; Falk T; Cowen SL
    Exp Neurol; 2021 Jun; 340():113670. PubMed ID: 33662379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
    Lindenbach D; Ostock CY; Eskow Jaunarajs KL; Dupre KB; Barnum CJ; Bhide N; Bishop C
    J Pharmacol Exp Ther; 2011 Jun; 337(3):755-65. PubMed ID: 21402691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
    Winkler C; Kirik D; Björklund A; Cenci MA
    Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
    Song L; Zhang Z; Hu R; Cheng J; Li L; Fan Q; Wu N; Gan J; Zhou M; Liu Z
    Drug Des Devel Ther; 2016; 10():547-55. PubMed ID: 26893543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
    BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
    Wang Y; Zhang GJ; Sun YN; Yao L; Wang HS; Du CX; Zhang L; Liu J
    Behav Brain Res; 2018 Jul; 347():175-183. PubMed ID: 29551735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
    Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
    Calabrese V; Picconi B; Heck N; Campanelli F; Natale G; Marino G; Sciaccaluga M; Ghiglieri V; Tozzi A; Anceaume E; Cuoc E; Caboche J; Conquet F; Calabresi P; Charvin D
    Neuropharmacology; 2022 Nov; 218():109205. PubMed ID: 35940348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE
    Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulation of BET proteins in levodopa-induced dyskinesia.
    A Figge D; Standaert DG
    Neurobiol Dis; 2017 Jun; 102():125-132. PubMed ID: 28286180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC; Varney MA; Newman-Tancredi A
    Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.